Bayer is defending Trasylol lawsuits from around the United States that could number in the thousands as patients and families become more aware of the serious side effects of this heart surgery medication.
Bayer is defending Trasylol lawsuits from around the United States that could number in the thousands as patients and families become more aware of the serious side effects of this heart surgery medication. Trasylol claims brought on behalf of individuals and families of heart surgery patients throughout the United States have been filed against the drug giant Bayer. Currently Trasylol lawsuits are being filed by individuals and families throughout the United States. No Trasylol class action lawsuit has been filed, however given the number of potential Trasylol victims, attorneys and courts will likely look to multidistrict litigation and class actions to more efficiently handle the growing number of cases.
Bayer’s growing Trasylol problems follow a number of reports of the drug’s more serious side effects. The Trasylol heart surgery medication has recently been associated with a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved by the Federal Drug Administration. Aprotinin is manufactured by Bayer under the brand name Trasylol. Until it was recently withdrawn from the market, Trasylol sales continued to increase even though studies indicated serious Trasylol kidney damage side effects.
In January 2006 the Food and Drug Administration began a closer examination of the safety of Trasylol following the publication of studies linking the drug to dangerous side effects including heart attacks, kidney problems and strokes. In light of the preliminary BART study information, the FDA anticipates re-evaluating the risks and benefits of Trasylol. The FDA worked with Bayer to carefully phase Trasylol out of the marketplace in an attempt to prevent shortages of other drugs used prevent excessive bleeding during cardiac surgery. This phase-out however, led to the continued use of Trasylol during bypass surgeries until May 2008.
A more recent observational study based on 69 leading cardiac centers throughout the world was published regarding Bayer Pharmaceutical